Comprehensive Approach Advised for Managing CV Risk in T2DM

FRIDAY, Jan. 14, 2022 (HealthDay News) -- A comprehensive approach is recommended for management of cardiovascular risk factors among patients with type 2 diabetes (T2D), according to an American Heart Association scientific statement published online Jan. 10 in Circulation.
Joshua J. Joseph, M.D., M.P.H., from The Ohio State University in Columbus, and colleagues developed a scientific statement based on current evidence relating to cardiovascular health in patients with T2D.
The researchers note that management of cardiovascular risk factors remains poor in T2D, with many patients not meeting control targets for hemoglobin A1c, blood pressure, low-density lipoprotein cholesterol, and body mass index. A comprehensive approach to management of all cardiovascular risk factors is recommended for patients with T2D, including glycemia, blood pressure, lipid abnormalities, thrombotic risk, obesity, and smoking. Lifestyle and pharmaceutical interventions with proven benefit are recommended using a patient-centered approach. In addition to clinical care and treatment, social determinants of health must be considered.
"Social determinants of health, which includes health-related behaviors, socioeconomic factors, environmental factors, and structural racism, have been recognized to have a profound impact on cardiovascular disease and type 2 diabetes outcomes," Joseph said in a statement. "People with type 2 diabetes face numerous barriers to health, including access to care and equitable care, which must be considered when developing individualized care plans with our patients."
Several authors disclosed financial ties to the pharmaceutical and medical device industries.
Related Posts
Cancer in Uninsured Often Diagnosed at More Advanced, Lethal Stage
THURSDAY, July 14, 2022 (HealthDay News) -- Not having health insurance can be...
There Are No Useful Monoclonal Antibody Treatments Left Against New COVID Variants
MONDAY, Dec. 5, 2022 (HealthDay News) -- The last of six COVID monoclonal...
Atrial Shunt No Benefit for Heart Failure With Preserved EF
FRIDAY, Feb. 4, 2022 (HealthDay News) -- For patients with heart failure and an...
